GLP-1 Daily: Ozempic & Wegovy News
Medicare's GLP-1 Bridge Three Months In; Korea's Homegrown Eppe Reaches Clinics at a Lower Starting Price; Pooled Trials Link Semaglutide to Slower Kidney Decline
Friday, October 30, 2026 · 8 min
A preliminary Truveta analysis finds GLP-1 prescribing to adults 65 and older stayed about 21 percent above June levels three months after the Medicare GLP-1 Bridge launched, while Hanmi's Eppe began prescriptions in South Korea at a starter price undercutting Mounjaro and Wegovy. A Novo-funded pooled analysis of SELECT, FLOW and SOUL links semaglutide to fewer major kidney outcomes.
Listen
Show notes
A preliminary Truveta analysis finds GLP-1 prescribing to adults 65 and older stayed about 21 percent above June levels three months after the Medicare GLP-1 Bridge launched, while Hanmi's Eppe began prescriptions in South Korea at a starter price undercutting Mounjaro and Wegovy. A Novo-funded pooled analysis of SELECT, FLOW and SOUL links semaglutide to fewer major kidney outcomes.
In this episode
- GLP-1 prescriptions still up three months into Medicare Bridge pilot — Truveta Research
“GLP-1 prescribing among adults aged 65 years and older increased from June to July following implementation of the Medicare GLP-1 Bridge and remained relatively stable thereafter, with prescribing 20.6% higher three months after implementation than in June. The initial increase…”
- Korea’s First Homegrown Obesity Drug Begins Prescriptions, Challenging Mounjaro on Price - Businesskorea — Choi Mun-hee
“Eppe’s main competitive advantage is its price. According to pharmaceutical industry sources, the supply price for the first four weeks of treatment is approximately 129,800 won ($97.20), about half the roughly 270,000 won for Eli Lilly’s Mounjaro and around 40% less than the…”
- Semaglutide Slows Kidney Function Decline in High-Risk Patients — Lisa Kuhns, PhD
“Semaglutide reduces clinically important kidney outcomes and slows kidney function decline, with benefits generally consistent across baseline kidney function, diabetes status, adiposity, and type of administration, according to results of a study published in The Lancet…”